Despite the disappointing Phase II results for suzetrigine, Vertex's strong position in the cystic fibrosis market, bolstered by the FDA approval of Alyftrek, ensures continued revenue. The company's diverse pipeline targeting various diseases suggests potential for long-term growth, balancing the short-term setback.